荣丰控股(000668) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥189,523,795.37, representing a significant increase of 1,171.96% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥13,556,986.43, a decrease of 31.19% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,584,009.98, reflecting a 33.59% increase compared to the previous year[4]. - The net profit for Q3 2022 was -11,848,479.78 CNY, compared to -48,240,537.98 CNY in the same period last year, indicating an improvement[25]. - The total operating profit for the quarter was 8,684,825.98 CNY, a significant recovery from a loss of -57,353,021.09 CNY in the previous year[25]. - The total comprehensive income attributable to the parent company was -27,785,192.83 CNY, an improvement from -45,334,596.42 CNY year-over-year[26]. Earnings Per Share - The basic earnings per share were -¥0.09, a decrease of 30.77% year-on-year[4]. - The diluted earnings per share were also -¥0.09, reflecting a 30.77% decline compared to the same period last year[4]. - Basic and diluted earnings per share were both -0.19 CNY, compared to -0.31 CNY in the same quarter last year[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,498,026,811.90, down 9.06% from the end of the previous year[5]. - As of September 30, 2022, total assets amounted to CNY 3,498,026,811.90, down from CNY 3,846,493,191.89 at the beginning of the year, reflecting a decrease of approximately 9.1%[22]. - The company's total liabilities decreased to CNY 1,584,940,357.43 from CNY 1,986,813,585.32, a reduction of about 20.2%[21]. - The equity attributable to shareholders increased to ¥1,229,161,545.89, marking a growth of 4.19% compared to the end of the previous year[5]. Cash Flow - The cash flow from operating activities was -¥90,988,568.63, indicating a significant decrease of 118.48% year-to-date[4]. - Cash flow from operating activities showed a net outflow of -90,988,568.63 CNY, down from a net inflow of 492,408,969.47 CNY in the same quarter last year[29]. - The company reported cash inflow from investment activities of 164,166,677.28 CNY, while cash outflow was 219,605,268.39 CNY, resulting in a net cash outflow of -55,438,591.11 CNY[29]. - Financing activities generated a cash inflow of 526,310,000.00 CNY, but the net cash outflow was -114,953,360.29 CNY, compared to -263,680,026.32 CNY in the previous year[30]. - Cash and cash equivalents were reported at CNY 82,349,479.44, a decrease from CNY 480,759,764.94 at the beginning of the year, representing a decline of approximately 82.8%[18]. - The cash and cash equivalents at the end of the period were 48,489,393.73 CNY, down from 94,037,723.76 CNY at the end of the previous year[30]. Government Subsidies and Acquisitions - The company reported government subsidies amounting to ¥3,561,887.13 for the current period, contributing to its financial performance[7]. - The company completed the acquisition of 100% equity in Hunan Weiyu Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary[17]. Share Transfer and Due Diligence - The company is in the process of transferring control to Hubei New Momentum Fund Management Co., Ltd., which will acquire approximately 29.90% of the company's shares[14]. - The company has engaged intermediaries to conduct due diligence and valuation for the ongoing share transfer process[14]. Non-Current Assets and Impairment Loss - The company’s non-current assets totaled CNY 732,052,364.22, an increase from CNY 647,387,474.81 at the beginning of the year, indicating a growth of about 13.1%[20]. - The company reported a credit impairment loss of -6,938,225.10 CNY for the quarter[25].